T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation

被引：1
作者：
Lucarelli B. [1 ]
Merli P. [1 ]
Strocchio L. [1 ]
Cefalo M.G. [1 ]
Brescia L.P. [1 ]
Locatelli F. [1 ,2 ]
机构：
[1] Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio, Rome
[2] Department of Pediatrics, University of Pavia, Pavia
来源：
Current Stem Cell Reports | 2015年 / 1卷 / 4期
基金：
欧盟地平线“2020”;
关键词：
Donor lymphocytes infusions; Hematopoietic stem cell transplantation; Immune reconstitution; Immunotherapy; T cell;
D O I：
10.1007/s40778-015-0027-z
中图分类号：
学科分类号：
摘要：
Many different studies have demonstrated that early recovery of the adaptive immune system after allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly sustained by peripheral expansion of donor-derived, mature lymphocytes transferred with the graft. Different approaches based on the infusion of donor T cells after HSCT have been developed mainly to accelerate immune recovery and to treat/prevent (a) malignancy recurrence, (b) life-threatening infections, and (c) immune-mediated disorders, such as graft-versus-host disease (GVHD). For many years, donor lymphocyte infusion (DLI) has been a widely used approach to prevent and to treat leukemia recurrence, to convert mixed chimerism into complete donor chimerism, and to accelerate immune reconstitution of patients after HSCT. More sophisticated strategies of adoptive infusion of T cell lines/clones capable of mediating a graft-versus-leukemia (GVL) response, while avoiding GVHD occurrence, or specific for the most life-threatening pathogens (e.g., cytomegalovirus, Epstein-Barr virus, and adenovirus) have been envisaged and successfully tested in pilot trials in the early post-transplantation period. Also, ex vivo expanded regulatory T (Treg) cells have been shown to be beneficial for preventing GVHD post-HSCT. In this review, we will focus on DLI as well as more complex cellular therapies that require extensive cell manipulation. © 2015, Springer International Publishing AG.
引用
收藏
页码：206 / 214
页数：8
相关论文
共 100 条
[1]  
Copelan E.A., Hematopoietic stem-cell transplantation, N Engl J Med, 354, 17, pp. 1813-1826, (2006)
[2]  
Bartelink I.H., Belitser S.V., Knibbe C.A., Et al., Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children, Biol Blood Marrow Transplant, 19, 2, pp. 305-313, (2013)
[3]  
Storek J., Gooley T., Witherspoon R.P., Et al., Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts, Am J Hematol, 54, 2, pp. 131-138, (1997)
[4]  
Savani B.N., Mielke S., Rezvani K., Et al., Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 13, 10, pp. 1216-1223, (2007)
[5]  
Berger M., Figari O., Bruno B., Et al., Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality, Bone Marrow Transplant, 41, 1, pp. 55-62, (2008)
[6]  
Parkman R., Cohen G., Carter S.L., Et al., Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation, Biol Blood Marrow Transplant, 12, 9, pp. 919-927, (2006)
[7]  
Kim D.H., Sohn S.K., Won D.I., Et al., Rapid helper T-cell recovery above 200 × 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation, Bone Marrow Transplant, 37, 12, pp. 1119-1128, (2006)
[8]  
Locatelli F., Giorgiani G., Di-Cesare-Merlone A., Et al., The changing role of stem cell transplantation in childhood, Bone Marrow Transplant, 41, pp. S3-S7, (2008)
[9]  
Yun H.D., Waller E.K., Finding the sweet spot for donor lymphocyte infusions, Biol Blood Marrow Transplant, 19, 4, pp. 507-508, (2013)
[10]  
Kolb H.J., Mittermuller J., Clemm C., Et al., Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood, 76, 12, pp. 2462-2465, (1990)
12345678910